parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in oligodendrocytes (196 nCPM)	1.00
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	2 Parkinson's papers of 204	0.85
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 11872

receipt 11880: ATL1 in dopamine neurons, braak

power: full sample +0.08 (p 0.761, n 18), 95% CI -0.40 to +0.53. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.09 (p 0.728, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.01 (p 0.956, n 18). could be the mix.
skeptic: leave-one-out range -0.02 to +0.20, sign flips 1; without severely affected donors +0.08 (p 0.761, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ATL1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 11879: ATL1 in oligodendrocytes, braak

power: full sample +0.12 (p 0.633, n 18), 95% CI -0.37 to +0.56. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.31 (p 0.211, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.21 (p 0.403, n 18). could be the mix.
skeptic: leave-one-out range +0.01 to +0.23, sign flips 0; without severely affected donors +0.12 (p 0.633, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ATL1 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts